PFIZER AND BIONTECH TO SUPPLY CANADA WITH THEIR BNT162 MRNA- BASED VACCINE CANDIDATE
August 05, 2020
- Supply to be provided over the course of 2021, subject to?Health Canada?approval
- Agreement is part of Pfizer's and?BioNTech's?global commitment to help address the pandemic
- Pfizer and?BioNTech?began a Phase 2b/3 safety and efficacy trial and remain on track to seek regulatory review as early as?October 2020?, and manufacture globally up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021